Neuroleptic malignant syndrome following administration of risperidone and lithium [3]

Journal of Clinical Psychopharmacology

Volumn 23, Issue 3, 2003, Pages 315-317

  Bourgeois, James A ^a   Kahn, Debra R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DANTROLENE; LITHIUM; OLANZAPINE; RISPERIDONE; VALPROATE SEMISODIUM;

ADULT; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HOSPITALIZATION; HUMAN; LABORATORY TEST; LETTER; MALE; MENTAL HOSPITAL; NEUROLEPTIC MALIGNANT SYNDROME; OBESITY; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; WEIGHT GAIN;

ADULT; HUMANS; LITHIUM CHLORIDE; MALE; NEUROLEPTIC MALIGNANT SYNDROME; RISPERIDONE;

EID: 0037707978     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200306000-00015     Document Type: Letter

References (20)

1. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41:79-83.
2. Pearlman CA. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol. 1986;6:257-273.
3. Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals. 2000;30: 314-321.
4. Rundell JR, Wise MG. Concise Guide to Consultation Psychiatry. 3rd Ed. Washington, DC: American Psychiatric Press, Inc.; 2000: 180-190.
5. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998; 155:1113-1116.
6. Bonwick RJ, Hopwood M, Morris PLP. Neuroleptic malignant syndrome and risperidone: a case report. Aus NZJ Psychiatry. 1996;30:419-421.
7. Bajjoka I, Patel T, O'Sullivan T. Risperidone-induced neuroleptic malignant syndrome. Ann Emerg Med. 1997;30:698-700.
8. Newman M, Anjee A, Jampala C. Atypical neuroleptic malignant syndrome associated with risperidone treatment. Am J Psychiatry. 1997;154:1475.
9. Reeves RR, Mack JE, Torres RA. Neuroleptic malignant syndrome during a change from haloperidol to risperidone. Ann Pharmacother. 2001;35:698-701.
10. Robb AS, Chang W, Lee HK, et al. Case study: risperidone-induced neuroleptic malignant syndrome in an adolescent. J Child Adolesc Psychopharmacol. 2000;10:327-330.
11. Sechi G, Agnetti V, Masuri R, et al. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry. 2000; 24:1043-1051.
12. Lee SI, Klesmer J, Hirsch BE. Neuroleptic malignant syndrome associated with use of risperidone, ritonavir, and indinavir: a case report. Psychosomatics. 2000;41:453-454.
13. Lee MS, Lee HJ, Kim L. A case of delayed NMS induced by risperidone. Psychiatr Serv. 2000;51:254-255.
14. Dursun SM, Oluboka OJ, Deverajan S, et al. High-dose vitamin E plus vitamin B6 treatment of risperidone-related neuroleptic malignant syndrome. J Psychopharmacol. 1998; 12:220-221.
15. Swanson SL, Price WA, McEvoy JP. Effects of concomitant risperidone and lithium treatment. Am J Psychiatry. 1995;152:1096.
16. Gleason PP, Conigliaro RL. Neuroleptic malignant syndrome with risperidone. Pharmacotherapy. 1997;17:617-621.
17. Pope HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Mental Dis. 1986;174:493-495.
18. Susman VL, Addonizio G. Reinduction of neuroleptic malignant syndrome by lithium. J Clin Psychopharmacol. 1987;7:339-341.
19. Gewirtz G, Squires-Wheeler E, Sharif Z, et al. Results of computerised tomography during first admission for psychosis. Br J Psychiatry. 1994;164:789-795.
20. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry. 1989;50:295-298.